Sean Bohen - Sep 1, 2021 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
PRESIDENT AND CEO, Director
Signature
/s/ John B. Moriarty, Jr., Attorney-in-Fact
Stock symbol
OLMA
Transactions as of
Sep 1, 2021
Transactions value $
-$21,972
Form type
4
Date filed
9/3/2021, 05:16 PM
Next filing
Sep 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Options Exercise $4.2K +871 +1.6% $4.82 55.1K Sep 1, 2021 Direct F1
transaction OLMA Common Stock Sale -$26.2K -871 -1.58% $30.05 54.3K Sep 1, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OLMA Stock Option (Right to Buy) Options Exercise $0 -871 -0.09% $0.00 975K Sep 1, 2021 Common Stock 871 $4.82 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,625 shares acquired under the issuer's Employee Stock Purchase Plan on May 14, 2021.
F2 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F3 The weighted average sale price for the transaction reported was $30.05, and the range of prices were between $30.01 and $30.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable.